DIPG-25. GENETIC ALTERATIONS TARGETING THE MAPK PATHWAY CONFERS PRECLINICAL SENSITIVITY TO TRAMETINIB IN A CO-CLINICAL TRIAL IN DIPG

The survival of children with DIPG remains dismal, and new treatments are desperately needed. The development of patient-specific in vitro and in vivo models represents one such opportunity, however the time taken to establish such models and the rapid disease progression has been thought to limit t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Izquierdo, Elisa, Carvalho, Diana, Boult, Jessica, Mackay, Alan, Temelso, Sara, Molinari, Valeria, Stubbs, Mark, Burke, Rosemary, Depani, Sarita, O’Hare, Patricia, Robinson, Simon, Hubank, Michael, Hargrave, Darren, Jones, Chris
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Diffuse Intrinsic Pontine Glioma (DIPG)
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477199/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.046
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg